Defilade Capital Management L.P. Has $41.11 Million Stake in Pfizer Inc. $PFE

Defilade Capital Management L.P. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 33.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,464,129 shares of the biopharmaceutical company’s stock after selling 739,375 shares during the quarter. Pfizer comprises approximately 5.8% of Defilade Capital Management L.P.’s portfolio, making the stock its 4th biggest position. Defilade Capital Management L.P.’s holdings in Pfizer were worth $41,113,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in PFE. Pine Valley Investments Ltd Liability Co raised its stake in Pfizer by 2.3% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 145,531 shares of the biopharmaceutical company’s stock worth $4,087,000 after buying an additional 3,281 shares in the last quarter. Farmers National Bank lifted its holdings in Pfizer by 1.9% in the first quarter. Farmers National Bank now owns 83,303 shares of the biopharmaceutical company’s stock worth $2,339,000 after buying an additional 1,546 shares during the period. Chelsea Counsel Co. bought a new stake in Pfizer during the 1st quarter valued at approximately $562,000. Wealthquest Corp boosted its position in Pfizer by 12.3% during the 1st quarter. Wealthquest Corp now owns 20,683 shares of the biopharmaceutical company’s stock valued at $581,000 after acquiring an additional 2,263 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in shares of Pfizer by 49.3% during the 1st quarter. Parallel Advisors LLC now owns 129,199 shares of the biopharmaceutical company’s stock worth $3,628,000 after acquiring an additional 42,667 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Pfizer Price Performance

Shares of NYSE PFE opened at $25.10 on Monday. The company has a 50 day simple moving average of $25.04 and a two-hundred day simple moving average of $26.16. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The company has a market capitalization of $143.06 billion, a price-to-earnings ratio of 19.16 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 131.30%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on PFE. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, April 10th. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. Finally, UBS Group restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a report on Wednesday, May 27th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.50.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.